Enveric Biosciences, Inc. (ENVB): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:05 ET
- Event date
- 2026-11-13
- Accession no.
- 0001493152-26-051708
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Enveric reports third-quarter results and EB-003 development update
Enveric reported a net loss attributable to stockholders of $2.5 million for the third quarter ended September 30, 2026, compared with $3.4 million a year earlier. Cash-on-hand was $5.6 million as of September 30, 2026. The company also reported EB-003 preclinical study findings and continued final IND-enabling activities for its planned IND application.
- Net loss attributable to stockholders was $2.5 million, compared with $3.4 million for the quarter ended September 30, 2025.
- Basic and diluted loss per share was $0.57, compared with $10.81 for the quarter ended September 30, 2025.
- Cash-on-hand was $5.6 million as of September 30, 2026.
- Enveric is advancing final IND-enabling activities for EB-003 ahead of a planned IND submission and first-in-human Phase 1 trial.
earningsproduct
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | form8-k.htm |
| EX-99.1 | EX-99.1 | ex99-1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.